Cangrelor
- Generic Name
- Cangrelor
- Brand Names
- Kengreal, Kengrexal
- Drug Type
- Small Molecule
- Chemical Formula
- C17H25Cl2F3N5O12P3S2
- CAS Number
- 163706-06-7
- Unique Ingredient Identifier
- 6AQ1Y404U7
- Background
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
- Indication
For use as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
- Associated Conditions
- Coronary Revascularization, Peri-procedural Myocardial Infarction, Thrombosis (Stent Thrombosis)
Cangrelor on Top of AnticoagUlation in Patients with MyocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest ReceiVIng VA-ECMO
- Conditions
- Cardiogenic ShockExtracorporeal Membrane Oxygenation ComplicationPlatelet Dysfunction
- Interventions
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 50
- Registration Number
- NCT06792643
- Locations
- 🇮🇹
IRCCS San Raffaele Hospital, Milan, Italy
Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary Intervention
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 80
- Registration Number
- NCT06089577
- Locations
- 🇮🇹
Division of Cardiology, University Hospital of Ferrara, Ferrara, Italy
🇮🇹Division of Cardiology - Federico II University Hospital, Naples, Italy
Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry
- Conditions
- Coronary Artery DiseaseMyocardial InfarctionBleeding
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Universita degli Studi di Genova
- Target Recruit Count
- 900
- Registration Number
- NCT05505591
- Locations
- 🇮🇹
Università degli Studi della Campania "Luigi Vanvitelli", Caserta, Italy
🇮🇹University of Genoa, Genova, Italy
Evaluation of Myocardial Reperfusion After Primary PCI in Patients With High Platelet Reactivity Treated by Cangrelor or Not
- Conditions
- ST-elevation Myocardial Infarction
- Interventions
- Procedure: standard PCI
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- University Hospital, Caen
- Target Recruit Count
- 128
- Registration Number
- NCT04927949
- Locations
- 🇫🇷
CAEN University Hospital, Caen, France
Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry)
- Conditions
- Percutaneous Coronary Intervention
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 100
- Registration Number
- NCT04790032
- Locations
- 🇮🇹
University Federico II of Naples, Napoli, Italy
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
- Conditions
- Coronary Artery DiseaseAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 359
- Registration Number
- NCT04668144
- Locations
- 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States
REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
- Target Recruit Count
- 368
- Registration Number
- NCT04667078
- Locations
- 🇫🇷
CHU Lyon, Lyon, France
🇫🇷CHU Bordeaux, Bordeaux, France
🇫🇷CHRU Lille, Lille, France
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 22
- Registration Number
- NCT04634162
- Locations
- 🇺🇸
University of Florida Jacksonville, Jacksonville, Florida, United States
Dutch Cangrelor Registry
- Conditions
- STEMI - ST Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation MICoronary Artery Disease
- First Posted Date
- 2019-10-24
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Isala
- Target Recruit Count
- 250
- Registration Number
- NCT04138641
- Locations
- 🇳🇱
R.S. Hermanides, Zwolle, Overijssel, Netherlands
Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI
- Conditions
- Out-Of-Hospital Cardiac ArrestAcute Coronary Syndrome
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2021-12-03
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 30
- Registration Number
- NCT04005729
- Locations
- 🇸🇮
University Medical Centre Ljubljana, Ljubljana, Slovenia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.